International Finance
Featured Healthcare

Mainz-based BioNTech to develop malaria vaccines with mRNA tech

BioNTech malaria_IFM_Image
The same technology was used to develop the Covid-19 vaccine

Germany-based biotechnology company BioNTech wants to eradicate malaria by using the revolutionary mRNA technology, media reports said. The same technology was used to develop the vaccine for the Covid-19 virus.

BioNTech has revealed that it will begin clinical malaria vaccine trials by the end of 2022. Malaria kills around 400,000 people each year, many of them being African children.

BioNTech CEO Ugur Sahin said in a statement, “We will do whatever it takes to develop a safe and effective mRNA-based malaria vaccine that will prevent the disease, reduce mortality and ensure a sustainable solution for the African continent and other regions affected by this disease.”

The breakthrough project is being backed by the World Health Organization, the Africa Centers for Disease Control and Prevention and the European Union.

Earlier this year, BioNTech announced that along with Pfizer, they have signed agreements to deliver 1.8 billion doses of Covid-19 vaccines this year, which is a big jump, considering 1.4 billion announced in March.

While releasing the statement of the first-quarter results, they also focused on the fact that the output capacity for the vaccine would reach around 3 billion doses by the end of 2021, and they expect to produce another 3 billion doses by the end of 2022.

Both BioNTech and Pfizer have not faced production setbacks which were witnessed by AstraZeneca and Johnson & Johnson. BioNTech also unveiled plans to set up a new factory in Singapore where they are expected to produce several hundred million doses of mRNA vaccines every year from 2023.

What's New

Start-up of the Week: The ‘Zipline’ way of serving humanity through drone-powered logistics

IFM Correspondent

Tesla shareholders advised to reject Elon Musk’s USD 56 billion pay

IFM Correspondent

MEDGULF: Shaping the future of insurance in Saudi Arabia with innovation & integrity

IFM Correspondent

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.